Metraipolis › archive › dc_5d9d5e5fedbc

Treatment continuation and factors associated with discontinuation with 3-month paliperidone palmitate in patients with schizophrenia: a post hoc analysis of… — Europe PMC PMID:41929365

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41929365
DOI
10.3389/fpsyt.2026.1751249
License (as archived)
solo-consultazione
Archived
2026-11-04T06:57:59.794Z
SHA-256 of the archived text
d7d4bdb89aa18f55b0568eb91ec4961dabce64fc09f57a772ef9216fc4c1a8e6
Stable URL of this page
https://metraipolis.com/documento/dc_5d9d5e5fedbc

How to cite

Treatment continuation and factors associated with discontinuation with 3-month paliperidone palmitate in patients with schizophrenia: a post hoc analysis of… — Europe PMC PMID:41929365 — Europe PMC (en), https://europepmc.org/article/MED/41929365 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_5d9d5e5fedbc (Metraipolis archive dc_5d9d5e5fedbc, sha256 d7d4bdb89aa18f55b0568eb91ec4961dabce64fc09f57a772ef9216fc4c1a8e6)
BibTeX
@misc{dc5d9d5e5fedbc,
  title = {Treatment continuation and factors associated with discontinuation with 3-month paliperidone palmitate in patients with schizophrenia: a post hoc analysis of… — Europe PMC PMID:41929365},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41929365},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_5d9d5e5fedbc; sha256 d7d4bdb89aa18f55b0568eb91ec4961dabce64fc09f57a772ef9216fc4c1a8e6},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41929365. Agents can read the archived copy with the MCP tool read_document.